Replies to post #307723 on Avid Bioservices Inc (CDMO)

[hutschi]

Then it´s "OLD" and we can forget it!?

Thanks
Hutschi

[biopharm]

CJ, thanks and it looks like PS Targeting was not included in the original patent by Dana Farber

Now to see PS Targeting included.... on top of the fact that Troy Luster was on the PS Targeting patents with Dr Phil Thorpe and Peregrine CEO Steve King, it makes me curious to what extent would Troy Luster play in this? Troy Luster went to Dana Farber and always wondered why and just another puzzle piece seeing Dana Farber come to realize PS Targeting was required

Link below pg 16/17 showing undisclosed drug with Evotec (worked with Troy Luster / Dana Farber

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106231165

_______

Sanofi and Novartis snap up immuno-oncology candidates
Separate licensing deals see the firms look to catch up with the category's leaders
11th January 2016

Sanofi and Novartis have added to their early-stage cancer immunotherapy pipelines with new licensing deals as they try to catch up with the leaders in the category.
Details of the Novartis agreement are sketchy, but the company says it has licensed four preclinical programmes from Massachusetts-based Surface Oncology's portfolio which target "regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment".
The candidates will be developed as monotherapies as well as in combination with Novartis' own pipeline of immuno-oncology candidates, which includes seven clinical programmes with five more scheduled to start trials this year.
Novartis' immuno-oncology aspirations gathered pace at the start of 2015 when it set up a dedicated R&D team led by cancer vaccine pioneer Glenn Dranoff, and the portfolio is currently led by chimeric antigen receptor T-cell (CART) candidate CTL109 which is in phase II trials for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and multiple myeloma.
Meanwhile, after some disappointments with in-house R&D, Sanofi's activities in immuno-oncology were kick-started by a $1.8bn alliance with Regeneron and a $1.5bn deal with BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
..
..
http://www.pmlive.com/pharma_news/sanofi_and_novartis_snap_up_immuno-oncology_candidates_903270?SQ_DESIGN_NAME=2&;

________ some tidbits of info below but digging deeper into Evotec ...etc


Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123807225